Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.
By A. Langer-Gould, S. Atlas, A. Green, A. Bollen, D. Pelletier. New England Journal of Medicine, 2005
960 citations recorded by the source corpus.
Subfields: Oncology, Pathology and Forensic Medicine, Plant Science
View Paper: https://www.semanticscholar.org/paper/7a181edb5c28a37c4696d17a6ae65ef7a1090c8a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Pathology and Forensic Medicine
In Plant Science
Citations in the corpus
- Neutrophils and immunity: challenges and opportunities (2006, background): “but have been associated with devastating infections in other”
- Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool (2011, background): “Unfortunately, in a subset of individuals, this treatment leads to the reactivation of viral infections and progressive multifocal leukoencephalopath”
- “Inside-Out” Signaling of Sphingosine-1-Phosphate: Therapeutic Targets (2008, background): “Recently, it has been reported that this combination therapy may even lead to the development of progressive multifocal leukoencephalopathy, a potentially life-threatening opportunistic infection (Kleinschmidt-DeMasters and Tyler, 2005; Langer-Gould et al., 2005).”
- Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS) (2011, methodology): “We mentioned the JC virus example above (Kleinschmidt-DeMasters and Tyler, 2005; Langer-Gould et al., 2005; Clifford et al., 2010).”
- Identification of a Third Human Polyomavirus (2007, background): “This disorder has recently received renewed attention after the occurrence of fatal cases among patients treated with natalizumab for multiple sclerosis (22, 24).”
- The safety and side effects of monoclonal antibodies (2010, positive): “In November 2004, natalizumab was approved by the US Food and Drug Administration for the treatment of relapsing-remitting multiple sclerosis, but it was suspended in February 2005 on the discovery of three cases of PML: two cases in patients with multiple sclerosi”
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. (2009, neutral): “treatments (range) 4 (1-14) 8 (3-10) 4 (1-14)”